CoChat

Regulation of T-cell activation and migration by the kinase TBK1 during neuroinflammation

Open access
Yu, Jiayi, Zhou, Xiaofei, Chang, Mikyoung, Nakaya, Mako, Chang, Jae-Hoon, Xiao, Yichuan, William Lindsey, J., Dorta-Estremera, Stephanie, Cao, Wei, Zal, Anna, Zal, Tomasz, Sun, Shao-Cong · 2015 · Nature Communications

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

Abstract

Development of an immune or autoimmune response involves T-cell activation in lymphoid organs and subsequent migration to peripheral tissues. Here we show that T-cell-specific ablation of the kinase TBK1 promotes T-cell activation but causes retention of effector T cells in the draining lymph node in a neuroinflammatory autoimmunity model, experimental autoimmune encephalomyelitis (EAE). At older ages, the T-cell-conditional TBK1-knockout mice also spontaneously accumulate T cells with activated phenotype. TBK1 controls the activation of AKT and its downstream kinase mTORC1 by a mechanism involving TBK1-stimulated AKT ubiquitination and degradation. The deregulated AKT-mTORC1 signalling in turn contributes to enhanced T-cell activation and impaired effector T-cell egress from draining lymph nodes. Treatment of mice with a small-molecule inhibitor of TBK1 inhibits EAE induction. These results suggest a role for TBK1 in regulating T-cell migration and establish TBK1 as a regulator of the AKT-mTORC1 signalling axis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/ncomms7074

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Activation of TBK1 and IKKε by T-cell activation signals. (a) IB analysis of phosphorylated (P-) TBK1 (Ser172) and total TBK1 in WT CD4+ T cells (6-week-old mice), stimulated with anti-CD3 plus anti-CD28 using a crosslinking method or with the mitogens PMA plus ionomycin. (b) CD4+ T cells from the indicated KO or T-cell-conditional KO (TKO) and internal WT control mice (6 weeks) were treated with PMA plus ionomycin. TBK1, IKKε and the canonical IKK complex were isolated by IP from the cell lysates and subjected to in vitro kinase assays (KA) using GST-IRF3 (for TBK1 and IKKε) or GST-IκBα (for IKK) recombinant proteins as substrates. (c) TBK1, IKKε and IKK kinase assays were performed using Jurkat and derivative cells as described in b. Data are representative of three or more independent experiments.
Figure 1 Activation of TBK1 and IKKε by T-cell activation signals. (a) IB analysis of phosphorylated (P-) TBK1 (Ser172) and total TBK1 in WT CD4+ T cells (6-week-old mice), stimulated with anti-CD3 plus anti-CD28 using a crosslinking method or with the mitogens PMA plus ionomycin. (b) CD4+ T cells from the indicated KO or T-cell-conditional KO (TKO) and internal WT control mice (6 weeks) were treated with PMA plus ionomycin. TBK1, IKKε and the canonical IKK complex were isolated by IP from the cell lysates and subjected to in vitro kinase assays (KA) using GST-IRF3 (for TBK1 and IKKε) or GST-IκBα (for IKK) recombinant proteins as substrates. (c) TBK1, IKKε and IKK kinase assays were performed using Jurkat and derivative cells as described in b. Data are representative of three or more independent experiments.CC BY · PubMed Central
Figure 2 TBK1 deficiency promotes T-cell activation and perturbs T-cell homeostasis. (a) A representative spleen picture and mean±s.d. values of spleen cell numbers of 4-month-old WT and Tbk1-TKO mice (each circle represents a mouse, n=8). (b) Proliferation and ELISA (IL-2, IFN-γ and GM-CSF) analyses of CD4+ T cells purified from the spleen of young (6 weeks, n=4) WT and TKO mice and stimulated for 48 h with the indicated concentrations of plate-bound anti-CD3 and anti-CD28. (c) Flow cytometric analyses of splenic CD4+ T cells stimulated for 4 h with PMA and ionomycin in the presence of monensin. Frequency of IFN-γ-producing and GM-CSF-producing T cells are presented as a representative fluorescence-activated cell sorting plot (left) and mean±s.d. values (right) of multiple mice (6 weeks, WT=3, TKO=4). (d,e) Flow cytometric analyses of the frequency of naïve (CD44loCD62Lhi) and memory (CD44hiCD62Llo) CD4+ T cells in WT and Tbk1-TKO (d, n=3) or WT and IKKε-KO (e, n=4) mice (6 weeks old). Numbers in quadrant indicate the percentage of cells among total CD4+ T cells. Data are representative plot (left) and mean±s.d. values (right). (f,g) Flow cytometric analysis of naïve (CD44loCD62Lhi) and memory (CD44hiCD62Llo) CD4+ T cells of lethally irradiated Rag1-KO mice reconstituted with a mixture (1:1 ratio) of bone marrow cells derived from WT B6.SJL (CD45.1+) and WT or TKO (CD45.2+) mice (n=6). Data are representative plot (f) and mean±s.d. values (g). Data represent mean±s.d. from three or more independent experiments. *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001; NS, non-significant as determined by two-tailed unpaired Student’s t-test, comparing the indicated groups.
Figure 2 TBK1 deficiency promotes T-cell activation and perturbs T-cell homeostasis. (a) A representative spleen picture and mean±s.d. values of spleen cell numbers of 4-month-old WT and Tbk1-TKO mice (each circle represents a mouse, n=8). (b) Proliferation and ELISA (IL-2, IFN-γ and GM-CSF) analyses of CD4+ T cells purified from the spleen of young (6 weeks, n=4) WT and TKO mice and stimulated for 48 h with the indicated concentrations of plate-bound anti-CD3 and anti-CD28. (c) Flow cytometric analyses of splenic CD4+ T cells stimulated for 4 h with PMA and ionomycin in the presence of monensin. Frequency of IFN-γ-producing and GM-CSF-producing T cells are presented as a representative fluorescence-activated cell sorting plot (left) and mean±s.d. values (right) of multiple mice (6 weeks, WT=3, TKO=4). (d,e) Flow cytometric analyses of the frequency of naïve (CD44loCD62Lhi) and memory (CD44hiCD62Llo) CD4+ T cells in WT and Tbk1-TKO (d, n=3) or WT and IKKε-KO (e, n=4) mice (6 weeks old). Numbers in quadrant indicate the percentage of cells among total CD4+ T cells. Data are representative plot (left) and mean±s.d. values (right). (f,g) Flow cytometric analysis of naïve (CD44loCD62Lhi) and memory (CD44hiCD62Llo) CD4+ T cells of lethally irradiated Rag1-KO mice reconstituted with a mixture (1:1 ratio) of bone marrow cells derived from WT B6.SJL (CD45.1+) and WT or TKO (CD45.2+) mice (n=6). Data are representative plot (f) and mean±s.d. values (g). Data represent mean±s.d. from three or more independent experiments. *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001; NS, non-significant as determined by two-tailed unpaired Student’s t-test, comparing the indicated groups.CC BY · PubMed Central
Figure 3 TBK1 is crucial for EAE induction. (a) EAE disease score of WT (n=5) and Tbk1-TKO (n=4) mice. (b) Haematoxylin and eosin (H&E), CD4 IHC, and Luxol Fast Blue (LFB) staining of spinal cord sections from MOG35–55-immunized WT and TKO EAE mice (28 day after immunization). Scale bars, 500 μm. Data are representative of three independent experiments. (c) Flow cytometry determining the mean±s.d. values of CD4+ T-cell number and CD8+ T-cell number recovered from the CNS of WT and Tbk1-TKO mice 18 days after EAE induction. (d–f) Flow cytometric analyses of CD4+ T cells from CNS, spleen and lymph nodes of the EAE-induced mice described in a (18 days after EAE induction). The T cells were stimulated for 4 h with PMA and ionomycin in the presence of monensin, followed by flow cytometry analysis of the IFN-γ, IL-17A and GM-CSF-producing cells. (g) Mean±s.d. values of absolute numbers of IFN-γ, IL-17A- and GM-CSF-producing CD4+ T cells recovered from the draining lymph node (dLN) of WT or Tbk1-TKO mice described in a. Data represent mean±s.d. from three or more independent experiments. *P<0.05; **P<0.01; ***P<0.001; NS, non-significant as determined by two-way analysis of variance with Bonferroni’s post test for EAE clinical scores analysis and two-tailed unpaired Student’s t-test for other analysis, comparing the indicated groups.
Figure 3 TBK1 is crucial for EAE induction. (a) EAE disease score of WT (n=5) and Tbk1-TKO (n=4) mice. (b) Haematoxylin and eosin (H&E), CD4 IHC, and Luxol Fast Blue (LFB) staining of spinal cord sections from MOG35–55-immunized WT and TKO EAE mice (28 day after immunization). Scale bars, 500 μm. Data are representative of three independent experiments. (c) Flow cytometry determining the mean±s.d. values of CD4+ T-cell number and CD8+ T-cell number recovered from the CNS of WT and Tbk1-TKO mice 18 days after EAE induction. (d–f) Flow cytometric analyses of CD4+ T cells from CNS, spleen and lymph nodes of the EAE-induced mice described in a (18 days after EAE induction). The T cells were stimulated for 4 h with PMA and ionomycin in the presence of monensin, followed by flow cytometry analysis of the IFN-γ, IL-17A and GM-CSF-producing cells. (g) Mean±s.d. values of absolute numbers of IFN-γ, IL-17A- and GM-CSF-producing CD4+ T cells recovered from the draining lymph node (dLN) of WT or Tbk1-TKO mice described in a. Data represent mean±s.d. from three or more independent experiments. *P<0.05; **P<0.01; ***P<0.001; NS, non-significant as determined by two-way analysis of variance with Bonferroni’s post test for EAE clinical scores analysis and two-tailed unpaired Student’s t-test for other analysis, comparing the indicated groups.CC BY · PubMed Central
Figure 4 TBK1 deficiency promotes T-cell retention in draining lymph nodes. (a) WT and Tbk1-TKO naïve CD4+ cells were labelled with CMRA and CFSE, respectively, and adoptively transferred into Tcrb/d-KO mice in a mixture (at 1:1 ratio). Cell distribution in different organs was analysed 16 h later by flow cytometry (n=4). (b) Lethally irradiated Rag1-KO mice were reconstituted with a mixture (1:1 ratio) of bone marrow cells isolated from Tbk1-TKO and GFP-expressing WT mice (n=10). The chimeric mice were immunized with MOG35–55 6 weeks after reconstitution. CNS and draining LN (dLN) CD4+ T cells were analysed based on GFP expression gated on CD4+ cell on day 14 after EAE induction. (c–e) WT and Tbk1-TKO naïve CD4+ cell were labelled with CMRA or CFSE respectively and adoptively transferred into WT mice at 1:1 ratio, followed by MOG35–55 immunization. Five days later, recipient mice were subjected to flow cytometry analysis of cell distribution in different organs (c) or confocal imaging of the differentially labelled T cells in a draining LN, showing the entire T-cell zone (left) and the peripheral region (right) (d, red, CMRA-labelled WT T cells; green, CFSE-labelled Tbk1-TKO T cells; blue, LYVE-1+lymphatic vessels). TKO:WT T-cell ratio in the T-cell zone (set at an index of 1:1) and lymphatic vessel are presented as mean±s.d. values of based on three experiments with a total of >500 T cells analysed (e). (f,g) Clinical scores (f) and flow cytometry analysis of CD4+ T cells (g, day 18) of Tcrb/d-KO mice undergoing passive EAE induction after being adoptively transferred with WT or Tbk1-TKO MOG-primed CD4+ T cells. (h) Flow cytometry analysis of CD4+ T cells in the indicated organs and tissues of WT mice adoptively transferred (for 4 days) with a mixture (1:1 ratio) of MOG-primed WT (CMRA labelled) and Tbk1-TKO (CFSE-labelled) CD4+ T cells (1:1 ratio). Data represent mean±s.d. from two or more independent experiments. *P<0.05; **P<0.01; ***P<0.001; ****P<0.001; NS, non-significant as determined by two-way analysis of variance with Bonferroni’s post test for EAE clinical scores analysis and two-tailed unpaired Student’s t-test for other analysis, comparing the indicated groups.
Figure 4 TBK1 deficiency promotes T-cell retention in draining lymph nodes. (a) WT and Tbk1-TKO naïve CD4+ cells were labelled with CMRA and CFSE, respectively, and adoptively transferred into Tcrb/d-KO mice in a mixture (at 1:1 ratio). Cell distribution in different organs was analysed 16 h later by flow cytometry (n=4). (b) Lethally irradiated Rag1-KO mice were reconstituted with a mixture (1:1 ratio) of bone marrow cells isolated from Tbk1-TKO and GFP-expressing WT mice (n=10). The chimeric mice were immunized with MOG35–55 6 weeks after reconstitution. CNS and draining LN (dLN) CD4+ T cells were analysed based on GFP expression gated on CD4+ cell on day 14 after EAE induction. (c–e) WT and Tbk1-TKO naïve CD4+ cell were labelled with CMRA or CFSE respectively and adoptively transferred into WT mice at 1:1 ratio, followed by MOG35–55 immunization. Five days later, recipient mice were subjected to flow cytometry analysis of cell distribution in different organs (c) or confocal imaging of the differentially labelled T cells in a draining LN, showing the entire T-cell zone (left) and the peripheral region (right) (d, red, CMRA-labelled WT T cells; green, CFSE-labelled Tbk1-TKO T cells; blue, LYVE-1+lymphatic vessels). TKO:WT T-cell ratio in the T-cell zone (set at an index of 1:1) and lymphatic vessel are presented as mean±s.d. values of based on three experiments with a total of >500 T cells analysed (e). (f,g) Clinical scores (f) and flow cytometry analysis of CD4+ T cells (g, day 18) of Tcrb/d-KO mice undergoing passive EAE induction after being adoptively transferred with WT or Tbk1-TKO MOG-primed CD4+ T cells. (h) Flow cytometry analysis of CD4+ T cells in the indicated organs and tissues of WT mice adoptively transferred (for 4 days) with a mixture (1:1 ratio) of MOG-primed WT (CMRA labelled) and Tbk1-TKO (CFSE-labelled) CD4+ T cells (1:1 ratio). Data represent mean±s.d. from two or more independent experiments. *P<0.05; **P<0.01; ***P<0.001; ****P<0.001; NS, non-significant as determined by two-way analysis of variance with Bonferroni’s post test for EAE clinical scores analysis and two-tailed unpaired Student’s t-test for other analysis, comparing the indicated groups.CC BY · PubMed Central
Figure 5 TBK1 stimulates AKT degradation and negatively regulates the activation of AKT and mTORC1 pathways. (a) IB analysis of phosphorylated (P-) AKT (Ser473), Foxo1 (Thr24), S6 (Ser235/236), S6K1 (Thr389), as well as their total protein controls in CD4+ T cells from WT and Tbk1-TKO mice (6 weeks old). (b) IB analysis of the indicated phosphorylated (P-) and total proteins in CD4+ T cells activated by anti-CD3 plus anti-CD28 using a crosslinking method. (c) IB analysis of the indicated phosphorylated (P-) and total proteins in CD4+ T cells isolated from day 18 EAE-induced WT or Tbk1-TKO mice. (d) AKT was isolated by IP from the lysates of thymocytes derived from WT or Tbk1-TKO mice (6 weeks old), and the ubiquitinated AKT (Ub-AKT) was detected by IB using an anti-ubiquitin antibody detecting K48-linked polyubiquitin chains. (e) IB analysis using WT CD4+ T cells, pretreated for 1 h with a TBK1 inhibitor, MRT67307, of solvent control dimethylsulphoxide (DMSO) and subsequently stimulated for the indicated times with anti-CD3 plus anti-CD28 in the presence of a protein synthesis inhibitor, cycloheximide. (f) IB analysis of endogenous AKT and Actin and exogenous FLAG-TBK1 in whole-cell lysates of HEK293T cells, transfected as indicated and subsequently incubated for 2 h with DMSO or MG132 (25 μM). An arrowhead indicates the non-specific band. (g) IB analysis of the indicated exogenous proteins in the whole-cell lysates of HEK293 cells transfected with HA-AKT WT or the indicated point mutants either in the presence (+) or absence (−) of FLAG-tagged TBK1. An arrowhead indicates the non-specific band. (h) IB analysis of whole-cell lysates of WT CD4+ T cells transduced with pMIGR1 retroviruses encoding WT or mutant forms of AKT as well as the GFP marker. (i) IB (left) and flow cytometry (right) analyses of splenic CD4+ T cells from WT or Tbk1-TKO mice treated injected (i.p) with rapamycin for 5 days (n=5). (j) IB analysis of CD4+ cells from spleen of the indicated mouse strains. (k,l) EAE disease score (k) and CD4+ T-cell number of draining LN and CNS (l, day27) (l) of the indicated mouse strains, immunized for EAE induction (n=4). (m) Quantitative PCR (qPCR) analysis of the indicated genes in freshly isolated naïve or memory CD4+ T cells from WT and Tbk1-TKO mice (n=4). (n) S1PR1 flow cytometry analysis in memory CD4+ cell of inguinal LN from WT or Tbk1-TKO mice. (o) qPCR analysis of KLF2 in CD4+ T cells treated for 1 h with either DMSO control or inhibitors for AKT (AKTi) or PI3 kinase (LY294002). Data represent mean±s.d. from two or more independent experiments. *P<0.05; **P<0.01; NS, non-significant as determined by two-way analysis of variance with Bonferroni’s post test for EAE clinical scores analysis and two-tailed unpaired Student’s t-test for other analysis, comparing the indicated groups.
Figure 5 TBK1 stimulates AKT degradation and negatively regulates the activation of AKT and mTORC1 pathways. (a) IB analysis of phosphorylated (P-) AKT (Ser473), Foxo1 (Thr24), S6 (Ser235/236), S6K1 (Thr389), as well as their total protein controls in CD4+ T cells from WT and Tbk1-TKO mice (6 weeks old). (b) IB analysis of the indicated phosphorylated (P-) and total proteins in CD4+ T cells activated by anti-CD3 plus anti-CD28 using a crosslinking method. (c) IB analysis of the indicated phosphorylated (P-) and total proteins in CD4+ T cells isolated from day 18 EAE-induced WT or Tbk1-TKO mice. (d) AKT was isolated by IP from the lysates of thymocytes derived from WT or Tbk1-TKO mice (6 weeks old), and the ubiquitinated AKT (Ub-AKT) was detected by IB using an anti-ubiquitin antibody detecting K48-linked polyubiquitin chains. (e) IB analysis using WT CD4+ T cells, pretreated for 1 h with a TBK1 inhibitor, MRT67307, of solvent control dimethylsulphoxide (DMSO) and subsequently stimulated for the indicated times with anti-CD3 plus anti-CD28 in the presence of a protein synthesis inhibitor, cycloheximide. (f) IB analysis of endogenous AKT and Actin and exogenous FLAG-TBK1 in whole-cell lysates of HEK293T cells, transfected as indicated and subsequently incubated for 2 h with DMSO or MG132 (25 μM). An arrowhead indicates the non-specific band. (g) IB analysis of the indicated exogenous proteins in the whole-cell lysates of HEK293 cells transfected with HA-AKT WT or the indicated point mutants either in the presence (+) or absence (−) of FLAG-tagged TBK1. An arrowhead indicates the non-specific band. (h) IB analysis of whole-cell lysates of WT CD4+ T cells transduced with pMIGR1 retroviruses encoding WT or mutant forms of AKT as well as the GFP marker. (i) IB (left) and flow cytometry (right) analyses of splenic CD4+ T cells from WT or Tbk1-TKO mice treated injected (i.p) with rapamycin for 5 days (n=5). (j) IB analysis of CD4+ cells from spleen of the indicated mouse strains. (k,l) EAE disease score (k) and CD4+ T-cell number of draining LN and CNS (l, day27) (l) of the indicated mouse strains, immunized for EAE induction (n=4). (m) Quantitative PCR (qPCR) analysis of the indicated genes in freshly isolated naïve or memory CD4+ T cells from WT and Tbk1-TKO mice (n=4). (n) S1PR1 flow cytometry analysis in memory CD4+ cell of inguinal LN from WT or Tbk1-TKO mice. (o) qPCR analysis of KLF2 in CD4+ T cells treated for 1 h with either DMSO control or inhibitors for AKT (AKTi) or PI3 kinase (LY294002). Data represent mean±s.d. from two or more independent experiments. *P<0.05; **P<0.01; NS, non-significant as determined by two-way analysis of variance with Bonferroni’s post test for EAE clinical scores analysis and two-tailed unpaired Student’s t-test for other analysis, comparing the indicated groups.CC BY · PubMed Central
Figure 6 A small-molecule inhibitor of TBK1 promotes AKT-mTORC1 activation and inhibits EAE induction. (a–d) WT mice were immunized for EAE induction. Starting from 4 days before the immunization, the mice were treated daily (via i.p. injection) with vehicle control or the TBK1 inhibitor amlexanox (25 mg per kg body weight) for 14 days (n=5). The immunized mice were monitored for EAE disease scores (a) or killed on day 22 post immunization for flow cytometric analysis of the indicated cell populations in the CNS (b) and peripheral lymphoid organs (c) or for IB analysis of the indicated phosphorylated (P-) and total proteins in the splenic CD4+ T cells (d). (e) EAE clinical score of SJL.J mice immunized with PLP139–151 to induce the remitting–relapsing EAE and then treated daily (via i.p. injection) with vehicle control or the TBK1 inhibitor amlexanox (25 mg per kg body weight) for 14 days starting from day 23 (n=5). Data represent mean±s.d. from two or more independent experiments. *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001; NS, non-significant as determined by two-way analysis of variance with Bonferroni’s post test for EAE clinical scores analysis and two-tailed unpaired Student’s t-test for other analysis, comparing the indicated groups.
Figure 6 A small-molecule inhibitor of TBK1 promotes AKT-mTORC1 activation and inhibits EAE induction. (a–d) WT mice were immunized for EAE induction. Starting from 4 days before the immunization, the mice were treated daily (via i.p. injection) with vehicle control or the TBK1 inhibitor amlexanox (25 mg per kg body weight) for 14 days (n=5). The immunized mice were monitored for EAE disease scores (a) or killed on day 22 post immunization for flow cytometric analysis of the indicated cell populations in the CNS (b) and peripheral lymphoid organs (c) or for IB analysis of the indicated phosphorylated (P-) and total proteins in the splenic CD4+ T cells (d). (e) EAE clinical score of SJL.J mice immunized with PLP139–151 to induce the remitting–relapsing EAE and then treated daily (via i.p. injection) with vehicle control or the TBK1 inhibitor amlexanox (25 mg per kg body weight) for 14 days starting from day 23 (n=5). Data represent mean±s.d. from two or more independent experiments. *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001; NS, non-significant as determined by two-way analysis of variance with Bonferroni’s post test for EAE clinical scores analysis and two-tailed unpaired Student’s t-test for other analysis, comparing the indicated groups.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 53 references

Cited by

See all 119

Metadata

Authors
Yu, J., Zhou, X., Chang, M., Nakaya, M., Chang, J.-H., Xiao, Y., William Lindsey, J., Dorta-Estremera, S., Cao, W., Zal, A., Zal, T., & Sun, S.-C.
Affiliations
  • The University of Texas MD Anderson Cancer Center (US)
  • University of Fukui (JP)
Corresponding author
Sun, Shao-Cong
Venue
Nature Communications
Published
2015-01-21
Volume
6
Issue
1
Pages
6074-6074
ISSN
2041-1723 (ISSN-L)
OpenAlex
W1963961512
Cited by
118
References
53
Citations by year
2026: 7 · 2025: 9 · 2024: 18 · 2023: 8 · 2022: 8 · 2021: 13 · 2020: 9 · 2019: 12 · 2018: 12 · 2017: 10 · 2016: 10 · 2015: 2
FWCI
5.58
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
Funders
  • National Institutes of Health (AI064639)
  • University of Texas MD Anderson Cancer Center (P30-CA-016672, AI057555, AI104519)
  • National Cancer Institute (R01CA181184, P30CA016672)
  • National Institute of General Medical Sciences (GM84459, R01GM084459)
  • National Institute of Allergy and Infectious Diseases (AI064639, R01AI057555, R37AI064639, R01AI064639, R01AI104519, AI104519, AI057555)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords
TBK1, T cell activation, T cell migration, neuroinflammation, experimental autoimmune encephalomyelitis, Akt, mTORC1, draining lymph nodes, TBK1 inhibitors, autoimmunity
MeSH terms
Mechanistic Target of Rapamycin Complex 1, Animals, Cell Movement, Cell Separation, Central Nervous System, Encephalomyelitis, Autoimmune, Experimental, Female, Gene Expression Regulation, Humans, Lymphocyte Activation, Macrophages, Male, Mice, Inbred C57BL, Orthomyxoviridae, Phenotype, Phosphorylation, T-Lymphocytes, Signal Transduction, CD4-Positive T-Lymphocytes, Autoimmunity, Protein Serine-Threonine Kinases, Mice, Knockout, CD8-Positive T-Lymphocytes, Jurkat Cells, Multiprotein Complexes, Mice, TOR Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.